

## Product datasheet for **SR300045**

### Actin (ACTA1) Human siRNA Oligo Duplex (Locus ID 58)

#### Product data:

|                     |   |
|---------------------|---|
| Product Type:       | siRNA Oligo Duplexes  |
| Purity:             | HPLC purified   |
| Quality Control:    | Tested by ESI-MS  |
| Sequences:          | Available with shipment   |
| Stability:          | One year from date of shipment when stored at -20°C.  |
| # of transfections: | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).  |
| Note:               | Single siRNA duplex (10nmol) can be ordered.  |
| RefSeq:             | <a href="#">NM_001100</a>   |
| UniProt ID:         | <a href="#">P68133</a>  |
| Synonyms:           | ACTA; ASMA; CFTD; CFTD1; CFTDM; MPFD; NEM1; NEM2; NEM3; SHPM  |
| Components:         | ACTA1 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 58)<br>Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol<br>Included - SR30005, RNase free siRNA Duplex Resuspension Buffer - 2 ml  |
| Summary:            | The product encoded by this gene belongs to the actin family of proteins, which are highly conserved proteins that play a role in cell motility, structure and integrity. Alpha, beta and gamma actin isoforms have been identified, with alpha actins being a major constituent of the contractile apparatus, while beta and gamma actins are involved in the regulation of cell motility. This actin is an alpha actin that is found in skeletal muscle. Mutations in this gene cause a variety of myopathies, including nemaline myopathy, congenital myopathy with excess of thin myofilaments, congenital myopathy with cores, and congenital myopathy with fiber-type disproportion, diseases that lead to muscle fiber defects with manifestations such as hypotonia. [provided by RefSeq, Sep 2019] |



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).